Crossmark

The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1186/s40545-023-00529-0

Published Online: 2024-03-11

Published Print: 2023-12-31

Update policy: https://doi.org/10.1080/tandf_crossmark_01

Authors

Sharman Moser, Sarah http://orcid.org/0000-0002-9745-2016
Tanser, Frank

Siegelmann-Danieli, Nava

Apter, Lior

Chodick, Gabriel

Solomon, Josie
License Information

Version of Record valid from 2023-12-31
More Information

Peer Review Statement: The publishing and review policy for this title is described in its Aims & Scope.

Aim & Scope: http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=jppp20

Publication History

Received: 2022-12-08

Accepted: 2023-02-07

Published: 2024-03-11

Document is current

Any future updates will be listed below